Joseph Tuscano

This study is testing a new two-step treatment for people with a high-risk, aggressive type of lymphoma who haven't had treatment yet. First, patients receive a targeted drug that seeks out and kills cancer cells, followed by a standard chemotherapy regimen. The goal is to see if…

This study is testing whether adding a new immune-boosting drug called epcoritamab to standard chemotherapy and a stem cell transplant can better control aggressive large B-cell lymphoma that has returned or not responded to prior treatment. It will involve about 25 adults whose …

This study is testing whether adding a new drug called odronextamab can improve the effectiveness of a powerful last-resort treatment (CAR-T therapy) for an aggressive type of blood cancer called DLBCL. The trial is for adults whose cancer has come back or hasn't responded to at …